Although treatment with anti-β2M mAbs or BTZ reduced tumor volume (P < 0.05, versus control mice), combination treatment was more efficacious than BTZ alone (Figure 6A and 6B; P < 0.01). The gene discussed is B2M; the disease is neoplasm.